Intestinal Ischemia Biomarker and Quality of Life of the Patients With Chronic Mesenteric Ischemia and Median Arcuate Ligament Syndrome
Plasma Alpha glutathione S transferase (Alpha GST) has been previously demonstrated to be raised in patients with chronic mesenteric ischemia (CMI) caused by atherosclerosis and in patients with median arcuate ligament syndrome (MALS). Raised plasma level of Alpha GST has been demonstrated to decrease or normalize after surgical treatment of patients with CMI and MALS as compared with healthy individuals. This study compares the plasma Alpha GST in patients with CMI and MALS with those with 1-Morbus Crohn, 2-Gallstone disease, and age-matched healthy individuals. Besides, changes in the health-related quality of life (QoL) will be investigated in the study individuals.
• For the patient groups :
• Group 1: Has CTA or ultrasound diagnosed MALS and is scheduled operative treatment.
• Group 2: Has CTA or ultrasound diagnosed CMI and is scheduled operative or endovascular treatment.
• For the control group:
• Group 3- Has ultrasound based diagnosis of cholelithiasis and is scheduled for cholecystectomy.
• Group 4- Has established Mb Crohn diagnosis and under gastric lab follow-up. Group 5- Young healthy blood donors of mean age 45 years and has excluded MALS or CMi with ultrasound.
• Group 6- Healthy blood donors of mean age 70 years and has excluded MALS or CMi with ultrasound.